Cost-Effectiveness of Biologics for Allergic Diseases

被引：23
作者：
Wu, Ann Chen [1 ,2 ]
Fuhlbrigge, Anne L. [3 ]
Robayo, Maria Acosta [1 ,2 ]
Shaker, Marcus [4 ,5 ,6 ,7 ]
机构：
[1] Harvard Med Sch, Ctr Healthcare Res Pediat, Dept Populat Med, Boston, MA USA
[2] Harvard Pilgrim Hlth Care Inst, Boston, MA USA
[3] Univ Colorado, Sch Med, Pulm Sci & Crit Care Med, Dept Med, Aurora, CO USA
[4] Dartmouth Hitchcock Med Ctr, Sect Allergy & Immunol, Lebanon, NH 03766 USA
[5] Geisel Sch Med Dartmouth, Dept Pediat, Hanover, NH USA
[6] Geisel Sch Med Dartmouth, Dept Med, Hanover, NH USA
[7] Geisel Sch Med Dartmouth, Dept Community & Family Med, Hanover, NH USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE | 2021年 / 9卷 / 03期
关键词：
Biologics; Monoclonal antibodies; mAbs; Cost-effectiveness; Allergic disease; ANTI-IGE ANTIBODY; JOINT TASK-FORCE; QUALITY-OF-LIFE; ANTI-IL-5 MEPOLIZUMAB THERAPY; ANTIIMMUNOGLOBULIN-E ANTIBODY; CHRONIC SPONTANEOUS URTICARIA; LONG-TERM CONTROL; MONOCLONAL-ANTIBODY; SEVERE ASTHMA; IMMUNOLOGY/AMERICAN-COLLEGE;
D O I：
10.1016/j.jaip.2020.10.009
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
The introduction of specific humanized monoclonal antibodies over the past 20 years has dramatically changed the treatment of allergic diseases. At present, 5 mAbs are licensed for treating moderate to severe allergic and eosinophilic asthma, atopic dermatitis, chronic spontaneous urticaria, chronic sinusitis with nasal polyps, and eosinophilic granulomatosis with polyangiitis. Given the high costs of biologics, understanding their cost-effectiveness is critical. As new biologics are developed and new indications are approved for existing biologics, the use of biologics for allergic diseases will increase. Conducting cost-effectiveness evaluations in parallel to efficacy and effectiveness trials will help patients, providers, payers, and policymakers in decision making. (C) 2020 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码：1107 / +
页数：13
相关论文
共 106 条
  • [51] Healthcare Bluebook, MAK SHOPP HEALTHC ES
  • [52] NEW CONCEPTS OF IGE REGULATION
    HEUSSER, CH
    BEWS, J
    BRINKMANN, V
    DELESPESSE, G
    KILCHHERR, E
    LEDERMANN, F
    LEGROS, G
    WAGNER, K
    [J]. INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1991, 94 (1-4): : 87 - 90
  • [53] AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis
    Hirano, Ikuo
    Chan, Edmond S.
    Rank, Matthew A.
    Sharaf, Rajiv N.
    Stollman, Neil H.
    Stukus, David R.
    Wang, Kenneth
    Greenhawt, Matthew
    Falck-Ytter, Yngve T.
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : 1776 - 1786
  • [54] Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis
    Hirano, Ikuo
    Dellon, Evan S.
    Hamilton, Jennifer D.
    Collins, Margaret H.
    Peterson, Kathryn
    Chehade, Mirna
    Schoepfer, Alain M.
    Safroneeva, Ekaterina
    Rothenberg, Marc E.
    Falk, Gary W.
    Assouline-Dayan, Yehudith
    Zhao, Qiong
    Chen, Zhen
    Swanson, Brian N.
    Pirozzi, Gianluca
    Mannent, Leda
    Graham, Neil M. H.
    Akinlade, Bolanle
    Stahl, Neil
    Yancopoulos, George D.
    Radin, Allen
    [J]. GASTROENTEROLOGY, 2020, 158 (01) : 111 - +
  • [55] Holgate S, 2001, CURR MED RES OPIN, V17, P233
  • [56] Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma
    Holgate, ST
    Chuchalin, AG
    Hébert, J
    Lötvall, J
    Persson, GB
    Chung, KF
    Bousquet, J
    Kerstjens, HA
    Fox, H
    Thirlwell, J
    Della Cioppa, G
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2004, 34 (04) : 632 - 638
  • [57] Hom Selina, 2017, P T, V42, P564
  • [58] Effects of Adding Omalizumab, an Anti-Immunoglobulin E Antibody, on Airway Wall Thickening in Asthma
    Hoshino, Makoto
    Ohtawa, Junichi
    [J]. RESPIRATION, 2012, 83 (06) : 520 - 528
  • [59] Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment):: INNOVATE
    Humbert, M
    Beasley, R
    Ayres, J
    Slavin, R
    Hébert, J
    Bousquet, J
    Beeh, KM
    Ramos, S
    Canonica, GW
    Hedgecock, S
    Fox, H
    Blogg, M
    Surrey, K
    [J]. ALLERGY, 2005, 60 (03) : 309 - 316
  • [60] Achieving the Quadruple Aim to deliver value-based allergy care in an ever-evolving health care system
    Iglesia, Edward G. A.
    Greenhawt, Matthew
    Shaker, Marcus S.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (02) : 126 - 136
12345678910